Моско́вский научно-иссле́довательский онкологи́ческий институ́т имени П. А. Ге́рцена Министерства здравоохранения Российской Федерации — одно из ведущих научных и лечебно-профилактических учреждений онкологического профиля в стране.

During the past decade, P.A. Herzen Oncological Inst. ; Oncology conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 17 clinical trials were completed, i.e. on average, 47.2% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 10 clinical trials were completed. i.e. 52.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "P.A. Herzen Oncological Inst. ; Oncology" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Janssen Research & Development, LLC" with 7 trials sponsored, "Bayer" with 3 trials sponsored, "AstraZeneca" with 2 trials sponsored and "Biocad" with 2 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "P.A. Herzen Oncological Inst. ; Oncology" #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Myriad Genetic Laboratories, Inc." with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator and "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "P.A. Herzen Oncological Inst. ; Oncology" are "Renal Cell Carcinoma" (4 trials), "Breast Cancer" (2 trials), "Cancer" (2 trials), "Carcinoma, Transitional Cell" (2 trials) and "Metastatic Prostate Cancer" (2 trials). Many other conditions were trialed in "P.A. Herzen Oncological Inst. ; Oncology" in a lesser frequency.

Most popular intervention types in "P.A. Herzen Oncological Inst. ; Oncology" are "Drug" (48 trials), "Biological" (9 trials), "Other" (5 trials), "Radiation" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (9 trials), "Placebo" (9 trials), "Paclitaxel" (7 trials), "Carboplatin" (6 trials) and "Bevacizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "P.A. Herzen Oncological Inst. ; Oncology" are 33 trials for "All" genders, 12 trials for "Male" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "P.A. Herzen Oncological Inst. ; Oncology". undefined are not yet recruiting, 11 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in P.A. Herzen Oncological Inst. ; Oncology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in P.A. Herzen Oncological Inst. ; Oncology, 3 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".